# Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

> **NCT04152018** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 85 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Ovarian Cancer
- Gastric Cancer
- Esophageal Cancer
- Lung Squamous Cell Carcinoma
- Pancreatic Cancer
- Bile Duct Cancer
- Endometrial Cancer
- Melanoma Cancer
- Urothelial Cancer

## Interventions

- **DRUG:** PF-06940434
- **DRUG:** PF-06801591

## Key facts

- **NCT ID:** NCT04152018
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-13
- **Primary completion:** 2024-12-10
- **Final completion:** 2024-12-10
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152018, "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04152018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*